Diversified Trust Co decreased its position in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 52.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 7,418 shares of the biotechnology company's stock after selling 8,258 shares during the quarter. Diversified Trust Co's holdings in Blueprint Medicines were worth $647,000 at the end of the most recent reporting period.
Other institutional investors have also recently bought and sold shares of the company. Quarry LP bought a new stake in shares of Blueprint Medicines during the 3rd quarter worth approximately $32,000. Covestor Ltd lifted its position in Blueprint Medicines by 206.7% during the third quarter. Covestor Ltd now owns 598 shares of the biotechnology company's stock worth $55,000 after acquiring an additional 403 shares during the last quarter. Quantbot Technologies LP bought a new stake in Blueprint Medicines in the 3rd quarter valued at $108,000. Values First Advisors Inc. bought a new stake in shares of Blueprint Medicines in the third quarter valued at about $122,000. Finally, CWM LLC grew its position in shares of Blueprint Medicines by 69.2% during the 3rd quarter. CWM LLC now owns 1,870 shares of the biotechnology company's stock worth $173,000 after purchasing an additional 765 shares in the last quarter.
In other Blueprint Medicines news, insider Ariel Hurley sold 1,819 shares of the stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $93.26, for a total transaction of $169,639.94. Following the sale, the insider now owns 14,967 shares in the company, valued at $1,395,822.42. This represents a 10.84 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Jeffrey W. Albers sold 15,000 shares of Blueprint Medicines stock in a transaction dated Thursday, December 19th. The shares were sold at an average price of $89.77, for a total value of $1,346,550.00. Following the transaction, the director now directly owns 157,557 shares of the company's stock, valued at $14,143,891.89. The trade was a 8.69 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 23,720 shares of company stock worth $2,177,846. Insiders own 4.21% of the company's stock.
Several analysts recently issued reports on the stock. JMP Securities reiterated a "market outperform" rating and set a $125.00 price target on shares of Blueprint Medicines in a research report on Monday, December 9th. UBS Group started coverage on Blueprint Medicines in a report on Thursday, October 24th. They set a "neutral" rating and a $88.00 price target on the stock. JPMorgan Chase & Co. initiated coverage on Blueprint Medicines in a report on Thursday, November 14th. They issued an "overweight" rating and a $126.00 price objective for the company. StockNews.com upgraded shares of Blueprint Medicines from a "sell" rating to a "hold" rating in a report on Friday, November 8th. Finally, Stephens reissued an "overweight" rating and issued a $140.00 price objective on shares of Blueprint Medicines in a research note on Thursday, January 2nd. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Blueprint Medicines has an average rating of "Moderate Buy" and an average price target of $123.33.
Check Out Our Latest Stock Analysis on Blueprint Medicines
BPMC opened at $87.43 on Friday. Blueprint Medicines Co. has a 1 year low of $72.24 and a 1 year high of $121.90. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.32 and a quick ratio of 3.27. The firm's fifty day moving average price is $93.48 and its two-hundred day moving average price is $95.63. The company has a market capitalization of $5.55 billion, a price-to-earnings ratio of -41.44 and a beta of 0.61.
Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last announced its earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.97) by $0.08. The firm had revenue of $128.20 million during the quarter, compared to analyst estimates of $127.56 million. Blueprint Medicines had a negative return on equity of 112.30% and a negative net margin of 29.48%. The business's revenue was up 126.5% compared to the same quarter last year. During the same period last year, the firm posted ($2.20) EPS. As a group, analysts anticipate that Blueprint Medicines Co. will post -3.68 earnings per share for the current fiscal year.
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Blueprint Medicines, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Blueprint Medicines wasn't on the list.
While Blueprint Medicines currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.